Top Markets
#1 Black Phoenix Black Phoenix +743.71%
#2 Beam Beam +43.17%
#3 THORChain THORChain +19.76%
#4 SAFEcoin SAFEcoin +18.44%
#5 TENDIES TENDIES +17.90%
#6 THORChain Yield THORChain Yield +17.02%
#7 MiL.k Alliance MiL.k Alliance +16.34%
#8 Wrapped STX (Velar) Wrapped STX (Velar) +15.76%
#9 Bless Bless +15.03%
#10 Tutorial Tutorial +13.90%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Pharvaris N.V. Pharvaris N.V.

Pharvaris N.V.

PHVS
Rank in Stocks #5577
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the... Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Share Price
$36.98
Last synced: 2026-08-26
Market Cap
$2.58B
Change (1 day)
-0.67%
Change (1 year)
55.51%
Country
NL
Trade Pharvaris N.V. (PHVS)

Category

Healthcare
Earnings for Pharvaris N.V. (PHVS)
Earnings in 2026 TTM: 0
According to Pharvaris N.V. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Pharvaris N.V. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH